Valitor is a pioneering brand that is engineering disruptive medicines to revolutionize the treatment of various diseases. Their innovative approach focuses on optimizing how and where disease mechanisms are targeted, ultimately producing the most significant clinical impact. One of their notable products, VLTR-557, is currently in development as a long-acting treatment for wet age-related macular degeneration (AMD), a vision-threatening disease.

Valitor's primary goal is to conquer the limitations of established drug targets by leveraging their multivalent biopolymer technology. They aim to maximize the benefits for patients by delivering more effective treatments for cancer therapies, durable treatments for vision-threatening diseases, and localized treatments for joint diseases. To achieve these goals, Valitor has assembled a team of seasoned biotechnology executives, innovative bioengineers, scientists, and leading drug developers.

They bring together their expertise to develop better medicines and improve patient outcomes, with a strong focus on ophthalmology and vision-threatening diseases. Valitor is dedicated to engineering better medicines, overcoming drug limitations, and making a significant impact in the field of healthcare